On the basis of these findings, we further developed a synthetic lethality therapy in which the STRIPAK assembly was targeted via a combination of approaches to recover the kinase activity of MST1/2 and therefore resensitize gastrointestinal tumors to the effects of PARPi. This evidence concerns the gene MST1 and digestive system neoplasm.